Newron Addresses FDA Hold on Schizophrenia Drug Study
Newron Pharmaceuticals held a call to discuss the FDA's clinical hold on U.S. study centers in the ENIGMA-TRS 2 trial. The company is reviewing the agency's feedback regarding safety concerns for its treatment-resistant schizophrenia candidate evenamide. Management also provided an update on the broader ENIGMA-TRS program.
Newron Pharmaceuticals convened an update call after receiving written feedback from the FDA concerning a clinical hold affecting U.S. sites in the ENIGMA-TRS 2 study. The company said it is examining that feedback while continuing work on the broader ENIGMA-TRS Phase III program.
The candidate, evenamide, is being developed for treatment-resistant schizophrenia and for schizophrenia patients with poor response. Newron noted its prior experience with sodium channel pharmacology, including Xadago, a marketed product with sodium channel blocking activity available in Europe for 11 years and the U.S. for 9 years. Management said few therapeutic choices remain.
If the U.S. hold persists, patients with treatment-resistant schizophrenia and their caregivers may face continued limited options, while clinicians could have fewer experimental pathways. Newron’s review of FDA feedback may affect trial enrollment and timelines, potentially influencing investor confidence and future access if the program advances. The broader impact depends on whether the agency’s safety questions are resolved and whether the ENIGMA-TRS program can continue.